Growth hormone: CJC-1295 research at AV Peptide
The long-acting form sustains a hormone signal for days. The pulses continue. Both observations matter before the claim turns to sleep or recovery.
DAC chemistry
The extra piece of chemistry does a remarkable amount of work. DAC, the Drug Affinity Complex, allows CJC-1295 to attach to albumin in circulating blood. That attachment helps the peptide persist. The shorter-acting material called Modified GRF (1-29), often described as “no-DAC”, lacks the albumin-binding addition. The review of growth hormone-releasing hormone analogues gives the broader pharmacological context.
The key human CJC-1295 studies concern the long-acting form. In my estimation, the duration has to stay attached to that form. A report that leaves the form unstated has omitted a consequential detail.
In healthy-adult research on prolonged stimulation, the estimated half-life was 5.8–8.1 days. Mean growth hormone increased for 6 days or more, and IGF-1 increased for 9–11 days after a single study administration. Those are observations from the experiment, rather than instructions for using the compound.
Prolonged stimulation and pulsatility
The word “continuous” made the second study sound, to me, as though the growth hormone trace might flatten into a steady elevated line. The actual finding was better than that simple picture.
Pulsatile secretion persisted during continuous CJC-1295 stimulation in healthy men. Average and trough growth hormone rose; the frequency and magnitude of the release bursts were unchanged. A higher background and continuing pulses can coexist. That is a precise endocrine result, with more texture than “growth hormone went up”.
The earlier healthy-adult study also found sustained IGF-1 elevation after repeated study administrations. Neither paper established improved sleep, faster healing, fat loss or greater strength. Its persistence is an impressive piece of engineering. A recovery claim still needs a recovery trial, such as the quite different question tested with ipamorelin.
Proteins and preparation identity
A study of serum proteins in healthy young men found changes in several proteins, with some signals correlating with IGF-1. The detection problem is intriguing: what else in blood changes when this system is stimulated? The paper leaves everyday wellbeing unmeasured.
In a different kind of laboratory work, analysts identified CJC-1295 in an unknown seized preparation. The preparation’s stated identity did not accurately describe its contents. That finding is a reason to take identity testing seriously; it says nothing about the quality of every other preparation.
Sleep and safety
Deeper sleep, easier recovery and a leaner appearance recur in community accounts. Puffiness, hand tingling, local irritation, flushing and occasional reports of fatigue, headache or altered blood sugar appear too. These are anecdotal accounts, not clinical evidence. Other compounds are often involved, and the CJC-1295 form may be unclear.
Sustained growth hormone and IGF-1 exposure raises questions about fluid retention, glucose regulation and unwanted cell growth. Those are safety concerns requiring longer studies, rather than demonstrated rates of harm from the small early human experiments. I’d put a substantial long-term trial of useful outcomes ahead of another hormone trace.
CJC-1295 has no approved human treatment use. The research also records prohibition in drug-tested sport. A research label provides no assurance of prescription-level identity or sterility. The comparison page places its blood findings alongside the fat outcomes actually measured with tesamorelin.